Company Valuation: Interpace Biosciences, Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2020 2021 2022 2023 2024 2025
Market Cap 1 12.69 31.18 4.437 4.693 11.87 5.448
Change - 145.72% -85.77% 5.76% 152.98% -54.11%
Enterprise Value (EV) 1 14.8 41.84 15.7 12.39 16.27 4.126
Change - 182.66% -62.47% -21.1% 31.32% -74.64%
P/E -0.43x -2.06x -0.2x 6.03x 6.84x 1.39x
PBR -0.44x -0.74x -0.07x -0.08x -5.36x 0.25x
PEG - 0x -0x -0x 0x 0x
Capitalization / Revenue 0.39x 0.75x 0.14x 0.12x 0.25x 0.14x
EV / Revenue 0.46x 1.01x 0.49x 0.31x 0.35x 0.11x
EV / EBITDA -0.7x -6.28x -12.3x 3.23x 1.93x 0.79x
EV / EBIT -0.56x -3.56x -4.09x 4.41x 2.01x 0.86x
EV / FCF -2.21x -25.8x -15.1x 2.93x 11.5x 0.81x
FCF Yield -45.2% -3.87% -6.64% 34.1% 8.66% 123%
Dividend per Share 2 - - - - - -
Rate of return - - - - - -
EPS 2 -36.61 -18.09 -25.91 0.8948 1.972 4.426
Distribution rate - - - - - -
Net sales 1 32.4 41.31 31.84 40.21 46.93 38.73
EBITDA 1 -21.15 -6.663 -1.28 3.837 8.408 5.209
EBIT 1 -26.56 -11.74 -3.84 2.811 8.108 4.784
Net income 1 -26.45 -14.94 -21.96 0.802 6.702 24.58
Net Debt 1 2.11 10.65 11.26 7.694 4.395 -1.322
Reference price 2 15.700 37.350 5.200 5.400 13.488 6.151
Nbr of stocks (in thousands) 808 835 853 869 880 886
Announcement Date 4/1/21 3/31/22 3/27/23 4/1/24 3/31/25 3/30/26
1USD in Million2USD
Estimates


P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- - - - 42.21M
-238.02x15.82x-283.59x-.--% 47.03B
24.05x2.19x12.38x0.87% 27.18B
16.34x1.28x7.28x5.36% 7.1B
1065.86x - - - 5.87B
52.23x9.63x33.18x0.96% 3.38B
-25.73x - - - 2.57B
-60.45x - - -.--% 2.32B
14.25x1.45x5.69x5.34% 1.97B
30.99x1.64x12.25x1.45% 1.89B
Average 97.72x 5.34x -35.47x 2% 9.94B
Weighted average by Cap. -41.38x 9.61x -144.59x 0.86%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA


  1. Stock Market
  2. Stocks
  3. IDXG.D Stock
  4. Valuation Interpace Biosciences, Inc.